Soltis Investment Advisors LLC Sells 34 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Soltis Investment Advisors LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 677 shares of the biopharmaceutical company’s stock after selling 34 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $482,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $127,489,000. KBC Group NV boosted its holdings in Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares during the last quarter. Icon Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares during the last quarter. Finally, State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.8 %

NASDAQ:REGN opened at $690.36 on Tuesday. The firm has a market capitalization of $75.86 billion, a price-to-earnings ratio of 18.03, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock’s 50 day moving average price is $715.81 and its two-hundred day moving average price is $909.02. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.86 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.51%.

Analyst Ratings Changes

A number of equities analysts have issued reports on REGN shares. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Barclays dropped their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.